Inhibition of IL-17 as a Pharmacological Approach for IBD

REFERENCES

• Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nature Rev/Drug Disc 2012;11(10):763–776.
   PubMed Web of Science ®Google Scholar
• Wright JF, Bennett F, Li B, The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17 RC receptor complex. J Immunol 2008;181(4):2799–2805.
   PubMed Web of Science ®Google Scholar
• Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res 2007;17(5):435–440.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick LR, Demi L, Hofmann C, et al. 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm Bowel Dis 2010;16(10):1763–1777.
   PubMed Web of Science ®Google Scholar
• Leppkes M, Becker C, Ivanov II, ROR gamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009;136(10):257–267.
   Google Scholar
• Zhang Z, Zheng M, Bindas J, Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006;12(5):382–388.
   PubMed Web of Science ®Google Scholar
• Strzepa A, Szczepanik M. IL-17 expressing cells as a potential therapeutic target for treatment of immunological disorders. Pharmacol Rep 2011;63(1):30–44.
   Google Scholar
• Fitzpatrick LR. Novel pharmacological approaches for inflammatory bowel disease: targeting key intracellular pathways and the IL-23/IL-17 axis. Int J Inflam 2012;2012:1–8.
   Google Scholar
• Cao AT, Yao S, Gong B, Th17 cells upregulate polymeric Ig receptor and intestinal IgA and contribute to intestinal homeostasis. J Immunol 2012;89(11):4666–4673.
   Google Scholar
• Ogawa A, Andoh A, Araki Y, Neutralization of IL-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 2004;110(1):55–62.
   PubMed Web of Science ®Google Scholar
• Hernandez-Santos H, Gaffen SL. Th17 cells in immunity to Candida albicans. Cell Host Microbe 2012;17(5):425–435.
   Google Scholar
• Gladiator A, Wangler N, Trautwein-Weidner K, Cutting edge: IL-17 secreting innate lymphoid cells are essential for host defense against fungal infection. J Immunol 2013;190(2):521–525.
   PubMed Web of Science ®Google Scholar
• Puel A, Cypowyj S, Bustamante J, Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011;332(6025):65–68.
   PubMed Web of Science ®Google Scholar
• Kuestner RE, Taft DW, Haran A, Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol 2007;179(8):5462–5473.
   PubMed Web of Science ®Google Scholar
• Zriouai S, Toh ML, Tournandre A, IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ cxc chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. J Immunol 2008;180(1):655–663.
   Google Scholar
• Hu Y, Ota N, Peng I, IL-17RC is required for IL-17A and IL-17F dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 2010;184(8):4307–4316.
   Google Scholar
• Monteleone I, Sarra M, Pallone F, Th-17 related cytokines in inflammatory bowel diseases: friend or foes? Curr Mol Med 2012;12(5):592–597.
   PubMed Web of Science ®Google Scholar
• Ito R, Kita M, Shin-Ya M, Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem Biophys Res Commun 2008;377(1):12–16.
   Google Scholar
• Yen D, Cheung J, Scheerans H, IL-23 is essential for T-cell mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006;116(5):1310–1316.
   PubMed Web of Science ®Google Scholar
• Buonocore S, Ahern PP, Uhlig HH, Innate lymphoid cells drive intelelukin-23-dependent innate intestinal pathology. Nature 2010;464(7293):1371–1375.
   PubMed Web of Science ®Google Scholar
• Wedebye Schmidt EG, Larsen HL, Kristensesn NN, Th17 cell induction and effects of Il-17A and IL-17F blockade in experimental colitis. Inflamm Bowel Dis 2013;19(8):1567–1576.
   Google Scholar
• Guan Q, Ma Y, Hillman CL, Targeting IL12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis. Mol Med 2011;17(7–8):646–656.
   Google Scholar
• Guan Q, Weiss CR, Qing G, An IL-17 peptide-based and virus-like particle vaccine enhances the bioactivity of IL-17 in vitro and in vivo. Immunotherapy 2012;4(12):1799–1807.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick LR, Small JS, Doblhofer R, Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. JPET 2012;342(3): 850–860.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands B, Lewitzky S, Secukinumab, a human anti-IL17a monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomized, double-blind placebo controlled trial. Gut 2012;61(12):1693–1700.
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Vermiere S, A randomized, double blind, placebo controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn's disease. Gastroenterology 2012;143(3):E26.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sendid B, Jouhalt T, Secukinumab failure in Crohn's disease: the yeast connection. Gut 2013;62(5):800–801.
   PubMed Web of Science ®Google Scholar
• Raine T, Kaser A. Seventeen in Crohn's disease. Less prime than we thought. Gut 2012;61(12): 1653–1654.
   PubMed Web of Science ®Google Scholar
• Herrlinger KR, Diculescu M, Fellerman K, Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study. J Crohn's Colitis 2013;7(8):636–643.
   Google Scholar
• Sandborn WJ, Ghosh S, Panes J, Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367(7):616–624.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, Phase 2 randomized study of CP-690,550, an oral janus kinase inhibitor, in active Crohn's disease. Gastroenterology 2011;140:S124.
   Google Scholar
• Sandborn WJ, Su C, Niezychowski W. Tofacitinib in active ulcerative colitis: response to the editor. 2012;367(20):1960–1961.
   Google Scholar
• Zorzi F, Monteleone I, Sarra M, Distinct profiles of effector cytokines mark the different phases of Crohn's disease. PLOS One 2013;8(10):1–10.
   Google Scholar
• Fitzpatrick LR, Meirelles K, Small JS, et al. A new model of chronic hapten-induced colitis in young rats. J Pediatr Gastroenterol Nutr 2010;50(3):240–250.
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Drja T, Effects of AIN457, a fully humanantibody to interleukin 17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2(52):ra72.
   Google Scholar
• Krueger JG, Fretzin S, Suarez-Farinas M, IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012;130(1):144–154.
   Google Scholar
• Lee YK, Turner H, Maynard CL, Late development plasticity in the T helper 17 lineage. Immunity 2009;30:92–107.
   PubMed Web of Science ®Google Scholar
• Maxwell J, Brown W, Zhang W, Modeling the distinct roles for IL-23 and IL-17 in inflammatory bowel disease using Mdr1a-/- mice. Gastroenterology 2013;144(Suppl 1):S-806.
   Google Scholar
• Papp KA, Leonardi C, Menter A, Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366(13):1181–1189.
   PubMed Web of Science ®Google Scholar
• Symons A, Zhang Y, Siegel LA, Differences between IL-17a and IL-17RA blockade in psoriasis and the role of IL-17C. Poster presentation at the IL-17 and related cytokines meeting, Dublin, Ireland. 2012.
   Google Scholar
• Papp KA, Reid C, Foley P, Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical resoponse in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol 2012;132(10):2466–2469.
   PubMed Web of Science ®Google Scholar
• Johansen C, Usher PA, Kjellerup RB, Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 2009;160(2):319–324.
   PubMed Web of Science ®Google Scholar
• Ramirez-Carozzi V, Sambandam A, Luis E, IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 2011;12(12):1159–1166.
   Google Scholar
• Im E, Jung J, Rhee SH. Toll-like receptor 5 engagement induces interleukin-17C expression in intestinal epithelial cells. J Interferon Cytokine Res 2012;32(12):583–591.
   Google Scholar
• Su J, Chen T, Ji XY, IL-25 downregulates th1/th17 immune response in an IL-10 dependent manner in inflammatory bowel disease. Inflamm Bowel Dis 2013;19(4):720–728.
   Google Scholar
• Reynolds JM, Martinez GJ, Nallaparaju KC, Cutting edge: regulation of intestinal inflammation and barrier function by IL-17C. J Immunol 2012;189(9):4226–4230.
   Google Scholar
• Maxwell J, Brown W, Rickel E, A pathogenic role for IL-17RB in intestinal inflammation. Gastroenterology 2010;138:(Suppl 1):S-260.
   Google Scholar
• Ho AW, Gaffen SL. IL-17RC: a partner in IL-17 signaling and beyond. Semin Immunopathol 2010;32 (1):33–42.
   PubMed Web of Science ®Google Scholar
• Fuss I. IL-17: intestinal effector or protector? Mucosal Immunol 2011;4(4):366–367.
   Google Scholar
• Kleinschek MA, Boniface K, Sadekova S, Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 2009;206(3):525–534.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X, Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186(7):4234–4243.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Maeshima K, Yamaoka K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis 2012;71(Suppl 2):i70–i74.
   Google Scholar
• Maeshima K, Yamaoka K, Kubo S, The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-y and interleukin-17 production by human CD4+ T cells. Arthritis Rheum 2012;64(6):1790–1798.
   PubMed Web of Science ®Google Scholar
• Kulkarni O, Sayyed SG, Kanter K, 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in mrl-(fas) ipr mice. Am J Pathol 2010;176(6):2840–2847.
   Google Scholar
• Tanaka Y, Yamaoka K. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol 2013;23(3):415–424.
   PubMed Web of Science ®Google Scholar
• O'Shea JJ. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72(Suppl 2):i111–i115.
   Google Scholar
• Cho ML, Kang JW, Moon YM, STAT3 and NF-κB pathways is required for IL-23 mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist deficient mice. J Immunol 2006;176(9):5652–5661.
   PubMed Web of Science ®Google Scholar
• Sutton C, Brereton C, Keogh B, A crucial role for interleukin (IL)-1 in the induction of IL-17- producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006;203(7):1685–1691.
   PubMed Web of Science ®Google Scholar
• Sutton CE, Lalor SJ, Sweeney CM, Interleukin-1 and IL-23 induce innate IL-17 production from δ T cells amplifying TH17 responses and autoimmunity. Immunity 2009;31(2):331–341.
   PubMed Web of Science ®Google Scholar
• Yurchenko E, Levings MK, Piccirillo C. CD4+Foxp3+ regulatory T cells suppress δ t-cell effector functions in a model of t-cell-induced mucosal inflammation. Eur J Immunol 2011;41(12):3455–3466.
   Google Scholar
• Coccia M, Harrison OJ, Schiering C, IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-A secreting innate lymphoid cells and CD4 +Th17 cells. J Exp Med 2012;209(9):1595–1609.
   PubMed Web of Science ®Google Scholar
• Geremia A, Araniciba-Carcamo CV, Fleming MP, IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 2011;208(6):1127–1133.
   PubMed Web of Science ®Google Scholar
• Sutton CE, Mielke LA, Mills KH. IL-17 producing δ T cells and innate lymphoid cells. Eur J Immunol 2012;42(9):2221–2231.
   PubMed Web of Science ®Google Scholar
• Huh JR, Littman Dr. Small molecule inhibitors of RORγT: targeting th17 cells and other applications. Eur J immunol 2012;42:2232–2237.
   PubMed Web of Science ®Google Scholar
• Kanai T, Mikami Y, Sujino T, RORγt-dependent IL-17A-producing cells in the pathogenesis of intestinal inflammation. Mucosal Immunol 2012;5(3):240–247.
   Google Scholar
• Vonarbourg C, Mortha A, Bui VL, Regulated expression of nuclear receptor RORγt confers distinct fates to NK cell-receptor expressing RORγt (+) innate lymphocytes. Immunity 2010;33(5):736–751.
   Google Scholar
• Lochner M, Ohnmacht C, Presley L, Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORγt and LTi cells. J Exp Med 2010;208(1):225–234.
   Google Scholar
• Ohnmacht C, Marques R, Presley L, Intestinal microbiota, evolution of the immune system and the bad reputation of pro-inflammatory immunity. Cell Microbiol 2011;13(5):653–659.
   PubMed Web of Science ®Google Scholar
• Symons A, Budelsky AL, Towne JE. Are Th17 cells in the gut pathogenic or protective? Mucosal Immunol 2012;5(1):4–6.
   Google Scholar
• Ono Y, Kanai T, Sujino T, T-helper and interleukin-17 producing lymphoid inducer-like cells make different contributions to colitis in mice. Gastroenterology 2012;143(5):1288–1297.
   Google Scholar
• Mudter J, Yu J, Zuffrey C, IRF4 regulates IL-17A promoter activity and controls RORγ-dependent Th17 colitis in vivo. Inflamm Bowel Dis 2011;17(6):1343–1358.
   Google Scholar
• Mudter J, Amoussina L, Schenk M, The transcription factor IFN regulatoryfactor-4 controls experimental colitis in mice via T-cell-derived IL-6. J Clin Invest 2008;118(7):2415–2426.
   Google Scholar
• Bai A, Lu N, Guo Y, All-trans retinoic acid down-regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis. J Leukoc Biol 2009;89:959–966.
   Google Scholar
• Rafa H, Saoula H, Belkhefa M, IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid. J Interferon Cytokine Res 2013;33(7):355–368.
   Google Scholar
• Osanai M, Nishikori N, Murata M, Cellular retinoic acid bioavailability determines epithelial integrity: role of retinoic acid receptor α agonists in colitis. Mol Pharmacol 2007;71(1):250–258.
   Google Scholar
• Wang Z, Bhattacharya N, Weaver M, Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2001;2(3):167–179.
   PubMedGoogle Scholar
• Shen YM, Zhao Y, Zeng Y, Inhibition of pim-1 kinase ameliorates dextran sodium sulfate-induced colitis in mice. Dig Dis Sci 2012;57(7):1822–1831.
   Google Scholar
• Shishodia S, Sethi G, Koopleva M, A synthetic triterpenoid CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor-kappa B-regulated gene products in human leukemic cells. Clin Cancer Res 2006;12(6):1828–1838.
   Google Scholar
• Ahmad R, Raina D, Meyer C, Triterpenoid CDDO-methyl ester inhibits the janus-activated kinase-1 and signal transducer and activator of transcription-3 (STAT) pathway by direct inhibition of JAK1 and STAT3. Cancer Res 2008;68(8):2920–2926.
   Google Scholar
• Yore MM, Liby KT, Honda T, The synthetic triterpenoid 1-{2-cyano-3, 12 dioxooleana-1,9 (11)-dien-28-oyl] Imidazole blocks nuclear factor-κB activation through direct inhibition of IκB kinase β. Mol Cancer Ther 2006;5(12):3232–3239.
   PubMed Web of Science ®Google Scholar
• Liby K, Voong N, Williams CR. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 2006; 12(14):4288–4293.
   Google Scholar
• Stonesifer E, Fitzpatrick LR, Small J, The synthetic triterpenoid (CDDO-IM) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis. Gastroenterology 2013;144(Suppl 1):S-807.
   Google Scholar
• Lee MJ, Lee JK, Cho JW, Interleukin-6 induces S100A9 expression in colonic epithelial cells through STAT3 activation in experimental ulcerative colitis. PLOS One 2012;7(9):1–11.
   Google Scholar
• Camporeale A, Poli V. IL-6, IL-17 and STAT3: a holy trinity in auto-immunity? Front Biosci 2012;17(6):2306–1726.
   Google Scholar